CBChristopher Barrett

Christopher Barrett

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Christopher Barrett has a total of 55 co-authors. Here are the top co-authors by number of shared publications:

  • Lohit Garg

    Department of Medicine Division of Cardiology, Section of Electrophysiology, University of Colorado Anschutz Medical Center Aurora Colorado USA

    5 shared publications
  • Wendy S. Tzou

    Cardiac Electrophysiology Section, Division of Cardiology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA

    5 shared publications
  • Paul Varosy

    Anschutz Medical Campus University of Colorado Aurora Colorado USA

    4 shared publications
  • Alexis Tumolo

    Anschutz Medical Campus University of Colorado Aurora Colorado USA

    3 shared publications
  • Amneet Sandhu

    Department of Medicine Division of Cardiology, Section of Electrophysiology, University of Colorado Anschutz Medical Center Aurora Colorado USA

    3 shared publications
  • John J. West

    Anschutz Medical Campus University of Colorado Aurora Colorado USA

    3 shared publications

Latest Publications

  • Clinical Predictors of Recurrent Cavotricuspid Isthmus Flutter After Catheter Ablation in Patients With Dextro‐Transposition of the Great Arteries

    by Alex Grubb, Radoslaw Nabrzyski, Nikhil Shamapant, Francis Zirille, Kishan Padalia, Lukasz Cerbin, Nicholas Holzemer, Michael A. Rosenberg, Lohit Garg, Christopher Barrett, et al.

    Introduction: Patients with surgically repaired D ‐transposition of the great arteries ( D ‐TGA) via atrial switch are at high risk of cavotricuspid isthmus (CTI) dependent atrial flutter, which can be challenging to address. High rates of CTI‐dependent flutter recurrence after initial ablation have been reported, but clinical predictors of recurrence remain poorly understood. Methods: We identified patients with a history of d ‐TGA repaired with atrial switch undergoing catheter ablation for CTI‐ dependent flutter from 2011 to 2023. Demographics, cardiac imaging, and procedural characteristics were analyzed. Clinical and procedural characteristics were compared between patients with and without recurrence. Results: Of 19 patients who underwent catheter ablation, 9 (47.3%) had recurrent CTI‐dependent flutter over a median follow‐up of 2.96 (IQR 0.88–5.08) years. Median recurrence time was 1.3 years (IQR 0.33–2.0) years postablation. Moderate or greater dilation of the systemic ventricle (100% vs. 54% p = 0.01) and systemic atrioventricular valve (AV) regurgitation (60% vs. 8% p = 0.01) correlated with recurrence. No differences were noted in need for pulmonary venous access, flutter cycle length, split duration, or transisthmus time. Conclusion: Nearly half of patients with repaired d ‐TGA undergoing index CTI‐dependent flutter ablation experience recurrence. Clinical and anatomic factors such as systolic dilation and AV regurgitation in the systemic ventricle were significantly associated with recurrence and provide operators with information on at‐risk profiles which may influence postprocedural care and monitoring.


  • PRIME score for prediction of permanent pacemaker implantation after transcatheter aortic valve replacement

    by Christopher D. Barrett, Andrew Nickel, Michael A. Rosenberg, Karen Ream, Wendy S. Tzou, Ryan Aleong, Alexis Tumolo, Lohit Garg, Matthew Zipse, John J. West, et al.

    Objectives: We sought to produce a simple scoring system that can be applied at clinical visits before transcatheter aortic valve replacement (TAVR) to stratify the risk of permanent pacemaker (PPM) after the procedure.Background: Atrioventricular block is a known complication of TAVR. Current models for predicting the risk of PPM after TAVR are not designed to be applied clinically to assist with preprocedural planning.Methods: Patients undergoing TAVR at the University of Colorado were split into a training cohort for the development of a predictive model, and a testing cohort for model validation. Stepwise and binary logistic regressions were performed on the training cohort to produce a predictive model. Beta coefficients from the binary logistic regression were used to create a simple scoring system for predicting the need for PPM implantation. Scores were then applied to the validation cohort to assess predictive accuracy.Results: Patients undergoing TAVR from 2013 to 2019 were analyzed: with 483 included in the training cohort and 123 included in the validation cohort. The need for a pacemaker was associated with five preprocedure variables in the training cohort: PR interval > 200 ms, Right bundle branch block, valve‐In‐valve procedure, prior Myocardial infarction, and self‐Expandable valve. The PRIME score was developed using these clinical features, and was highly accurate for predicting PPM in both the training and model validation cohorts (area under the curve 0.804 and 0.830 in the model training and validation cohorts, respectively).Conclusions: The PRIME score is a simple and accurate preprocedural tool for predicting the need for PPM implantation after TAVR.


  • Open Access

    Evaluation of Quantitative Decision‐Making for Rhythm Management of Atrial Fibrillation Using Tabular Q‐Learning

    by Christopher D. Barrett, Yuto Suzuki, Sundos Hussein, Lohit Garg, Alexis Tumolo, Amneet Sandhu, John J. West, Matthew Zipse, Ryan Aleong, Paul Varosy, et al.

    Background: Rhythm management is a complex decision for patients with atrial fibrillation (AF). Although clinical trials have identified subsets of patients who might benefit from a given rhythm‐management strategy, for individual patients it is not always clear which strategy is expected to have the greatest mortality benefit or durability. Methods and Results: In this investigation 52 547 patients with a new atrial fibrillation diagnosis between 2010 and 2020 were retrospectively identified. We applied a type of artificial intelligence called tabular Q‐learning to identify the optimal initial rhythm‐management strategy, based on a composite outcome of mortality, change in treatment, and sustainability of the given treatment, termed the reward function. We first applied an unsupervised learning algorithm using a variational autoencoder with K‐means clustering to cluster atrial fibrillation patients into 8 distinct phenotypes. We then fit a Q‐learning algorithm to predict the best outcome for each cluster. Although rate‐control strategy was most frequently selected by treating providers, the outcome was superior for rhythm‐control strategies across all clusters. Subjects in whom provider‐selected treatment matched the Q‐table recommendation had fewer total deaths (4 [8.5%] versus 473 [22.4%], odds ratio=0.32, P =0.02) and a greater reward ( P =4.8×10 −6 ). We then demonstrated application of dynamic learning by updating the Q‐table prospectively using batch gradient descent, in which the optimal strategy in some clusters changed from cardioversion to ablation. Conclusions: Tabular Q‐learning provides a dynamic and interpretable approach to apply artificial intelligence to clinical decision‐making for atrial fibrillation. Further work is needed to examine application of Q‐learning prospectively in clinical patients.


  • Evaluating temperature gradients across the posterior left atrium with radiofrequency ablation

    by Amneet Sandhu, Blair Holman, Steven Lammers, Lukasz Cerbin, Christopher Barrett, Rafay Sabzwari, Lohit Garg, Matthew M. Zipse, Alexis Z. Tumolo, Ryan G. Aleong, et al.

    Introduction: Esophageal injury is a well‐known complication associated with catheter ablation. Though novel methods to mitigate esophageal injury have been developed, few studies have evaluated temperature gradients with catheter ablation across the posterior wall of the left atrium, interstitium, and esophagus.Methods: To investigate temperature gradients across the tissue, we developed a porcine heart–esophageal model to perform ex vivo catheter ablation on the posterior wall of the left atrium (LA), with juxtaposed interstitial tissue and esophagus. Circulating saline (5 L/min) was used to mimic blood flow along the LA and alteration of ionic content to modulate impedance. Thermistors along the region of interest were used to analyze temperature gradients. Varying time and power, radiofrequency (RF) ablation lesions were applied with an externally irrigated ablation catheter. Ablation strategies were divided into standard approaches (SAs, 10–15 g, 25–35 W, 30 s) or high‐power short duration (HPSD, 10–15 g, 40–50 W, 10 s). Temperature gradients, time to the maximum measured temperature, and the relationship between measured temperature as a function of distance from the site of ablation was analyzed.Results: In total, five experiments were conducted each utilizing new porcine posterior LA wall‐esophageal specimens for RF ablation (n = 60 lesions each for SA and HPSD). For both SA and HPSD, maximum temperature rise from baseline was markedly higher at the anterior wall (AW) of the esophagus compared to the esophageal lumen (SA: 4.29°C vs. 0.41°C, p < .0001 and HPSD: 3.13°C vs. 0.28°C, p < .0001). Across ablation strategies, the average temperature rise at the AW of the esophagus was significantly higher with SA relative to HPSD ablation (4.29°C vs. 3.13°C, p = .01). From the start of ablation, the average time to reach a maximum temperature as measured at the AW of the esophagus with SA was 36.49 ± 12.12 s, compared to 16.57 ± 4.54 s with HPSD ablation, p < .0001. Fit to a linear scale, a 0.37°C drop in temperature was seen for every 1 cm increase in distance from the site of ablation and thermistor location at the AW of the esophagus.Conclusion: Both SA and HPSD ablation strategies resulted in markedly higher temperatures measured at the AW of the esophagus compared to the esophageal lumen, raising concern about the value of clinical intraluminal temperature monitoring. The temperature rise at the AW was lower with HPSD. A significant time delay was seen to reach the maximum measured temperature and a modest increase in distance between the site of ablation and thermistor location impacted the accuracy of monitored temperatures.

  • Multicenter experience with andexanet alfa for refractory pericardial bleeding during catheter ablation of atrial fibrillation

    by Tarek Zghaib, John D. Allison, Christopher Barrett, Jeffrey Arkles, Benjamin D'SOuza, Jeffrey Luebbert, Fermin Garcia, E. Kevin Heist, Wendy Tzou, David Callans, et al.

    Introduction: Pericardial bleeding is a rare but life‐threatening complication of atrial fibrillation (AF) ablation. Patients taking uninterrupted oral anticoagulation (AC) may be at increased risk for refractory bleeding despite pericardiocentesis and administration of protamine. In such cases, andexanet alfa can be given to reverse rivaroxaban or apixaban. In this study, we aim to describe the rate of acute hemostasis and thromboembolic complications with andexanet for refractory pericardial bleeding during AF ablation.Methods and Results: In this multicenter, case series, participating centers identified patients who received a dose of apixaban or rivaroxaban within 24 h of AF ablation, developed refractory pericardial bleeding during the procedure despite pericardiocentesis and administration of protamine and received andexanet. Eleven patients met inclusion criteria, with mean age of 73.5 ± 5.3 years and median CHA2DS2‐VASc score 4 [3–5]. All patients received protamine and pericardiocentesis, and 9 (82%) received blood products. All patients received a bolus of andexanet followed, in all but one, by a 2‐h infusion. Acute hemostasis was achieved in eight patients (73%) while three required emergent surgery. One patient (9%) experienced acute ST‐elevation myocardial infarction after receiving andexanet. Therapeutic AC was restarted after a mean of 2.2 ± 1.9 days and oral AC was restarted after a mean of 2.9 ± 1.6 days, with no recurrent bleeding.Conclusion: In patients on uninterrupted apixaban or rivaroxaban, who develop refractory pericardial bleeding during AF ablation, andexanet can achieve hemostasis thereby avoiding the need for emergent surgery. However, there is a risk of thromboembolism following administration.


  • Open Access

    Qualitative Evaluation of an Artificial Intelligence–Based Clinical Decision Support System to Guide Rhythm Management of Atrial Fibrillation: Survey Study

    by John Stacy, Rachel Kim, Christopher Barrett, Balaviknesh Sekar, Steven Simon, Farnoush Banaei-Kashani, Michael A Rosenberg

    Background: Despite the numerous studies evaluating various rhythm control strategies for atrial fibrillation (AF), determination of the optimal strategy in a single patient is often based on trial and error, with no one-size-fits-all approach based on international guidelines/recommendations. The decision, therefore, remains personal and lends itself well to help from a clinical decision support system, specifically one guided by artificial intelligence (AI). QRhythm utilizes a 2-stage machine learning (ML) model to identify the optimal rhythm management strategy in a given patient based on a set of clinical factors, in which the model first uses supervised learning to predict the actions of an expert clinician and identifies the best strategy through reinforcement learning to obtain the best clinical outcome—a composite of symptomatic recurrence, hospitalization, and stroke. Objective: We qualitatively evaluated a novel, AI-based, clinical decision support system (CDSS) for AF rhythm management, called QRhythm, which uses both supervised and reinforcement learning to recommend either a rate control or one of 3 types of rhythm control strategies—external cardioversion, antiarrhythmic medication, or ablation—based on individual patient characteristics. Methods: Thirty-three clinicians, including cardiology attendings and fellows and internal medicine attendings and residents, performed an assessment of QRhythm, followed by a survey to assess relative comfort with automated CDSS in rhythm management and to examine areas for future development. Results: The 33 providers were surveyed with training levels ranging from resident to fellow to attending. Of the characteristics of the app surveyed, safety was most important to providers, with an average importance rating of 4.7 out of 5 (SD 0.72). This priority was followed by clinical integrity (a desire for the advice provided to make clinical sense; importance rating 4.5, SD 0.9), backward interpretability (transparency in the population used to create the algorithm; importance rating 4.3, SD 0.65), transparency of the algorithm (reasoning underlying the decisions made; importance rating 4.3, SD 0.88), and provider autonomy (the ability to challenge the decisions made by the model; importance rating 3.85, SD 0.83). Providers who used the app ranked the integrity of recommendations as their highest concern with ongoing clinical use of the model, followed by efficacy of the application and patient data security. Trust in the app varied; 1 (17%) provider responded that they somewhat disagreed with the statement, “I trust the recommendations provided by the QRhythm app,” 2 (33%) providers responded with neutrality to the statement, and 3 (50%) somewhat agreed with the statement. Conclusions: Safety of ML applications was the highest priority of the providers surveyed, and trust of such models remains varied. Widespread clinical acceptance of ML in health care is dependent on how much providers trust the algorithms. Building this trust involves ensuring transparency and interpretability of the model.


  • Open Access

    Application of quantitative methods to selection of rhythm management strategies in patients with newly diagnosed atrial fibrillation: a retrospective observational study (Preprint)

    by Christopher D Barrett, Rachel Kim, Eric Sink, Alexis Tumolo, Matthew Zipse, Ryan Aleong, Lohit Garg, Amneet Sandhu, John J. West, Paul Varosy, et al.

    BACKGROUND Decisions regarding initial rhythm management strategy for patients with newly diagnosed atrial fibrillation (AF) are challenging to individualize. Prior work by our team has demonstrated feasibility of using machine learning algorithms at the level of diagnostic codes to predict rhythm management strategies; however, this work did not examine prediction models at the individual level. OBJECTIVE We aimed to examine decisions about rhythm management for AF and associated outcomes at the individual patient level, through mapping clinical trajectories within the electronic health record. We examined use of quantitative methods to predict the use of rate- or rhythm-control therapy in patients with a new diagnosis of AF. METHODS We performed a targeted chart review of patients with a new diagnosis of atrial fibrillation in the University of Colorado healthcare system from 2011 to 2020. We used clinical and demographic information to develop and test machine learning algorithms for predicting initial rhythm management strategy, and compared models based on accuracy as well as interpretability. Time-to-event and regression analyses were performed to predict the likelihood of change in rhythm management and the risk of subsequent hospitalization or death. RESULTS Of 419 patients with an EHR-diagnosis of new AF, we confirmed the diagnosis in 289 patients, 194 of whom we classified as paroxysmal and 95 persistent. For all patients with AF, rhythm-control therapy resulted in more total management changes. For paroxysmal AF, rhythm-control therapy resulted in fewer hospitalizations (incidence rate ratio 0.32, 95% CI 0.19-0.34) and no difference in mortality compared to rate-control therapy. For persistent AF, rhythm control resulted in more hospitalizations (incidence rate ratio 2.44, 95% CI 1.41-4.22) with no difference in mortality. Machine learning models could predict the initial strategy with limited accuracy, which was higher in patients with persistent than paroxysmal AF. CONCLUSIONS Quantitative decision models for rhythm management of AF can be developed through trajectory mapping using chart review. Discussion about patient-centered outcomes should be considered when selecting initial therapy for atrial fibrillation. CLINICALTRIAL n/a